Asia Beckons: Italy’s Menarini Wins Invida To Maximize Local Identity
This article was originally published in The Pink Sheet Daily
Executive Summary
Menarini is attracted to Invida for its speedy growth at the back of its Asia presence. Asia-Pacific region represents 10% of the world’s pharmaceutical market with a projected near-term 20% annual growth rate.
You may also be interested in...
China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products
SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners
Invida Goes Deeper In Skincare, Teams With Sinclair To Expand In Asia Pacific
UK specialty drug maker Sinclair signed a collaborative deal Dec. 7 with Singapore-based Invida to commercialize a number of dermatology products in 11 Asian markets. While multinational drug makers are accelerating expansion in Asia, specialty pharmaceutical companies are teaming up with contract sales firms such as Invida to capitalize on increasing demand in the region